Gland Pharma (NSE:GLAND) Other Long-Term Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAND Gland Pharma Ltd NSE:GLAND
80 GF Score
Price ₹2,858.60
GF Value ₹2,241.20
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Gland Pharma Other Long-Term Liabilities?

Gland Pharma NSE:GLAND -1.77% 80 Other Long-Term Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 80/100 and a GF Value™ of ₹2,241.20 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Gland Pharma's other long-term liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Gland Pharma's quarterly other long-term liabilities increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹2,556 Mil) but then declined from Mar. 2026 (₹2,556 Mil) to Jun. 2026 (₹0 Mil).

Gland Pharma's annual other long-term liabilities declined from Mar. 2024 (₹2,606 Mil) to Mar. 2025 (₹2,562 Mil) and declined from Mar. 2025 (₹2,562 Mil) to Mar. 2026 (₹2,556 Mil).

Gland Pharma Other Long-Term Liabilities Related Terms

Gland Pharma Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Other Long-Term Liabilities Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only 894.93 859.36 2,606.09 2,561.92 2,556.28

Gland Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4,274.08 0.00 2,556.28 0.00
NSE:GLAND
80GF Score
Gland Pharma Ltd NSE:GLAND
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of ₹0 Mil mean?
Gland Pharma (NSE:GLAND) has a Other Long-Term Liabilities of ₹0 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Other Long-Term Liabilities too high?
Gland Pharma's current Other Long-Term Liabilities is ₹0 Mil. Overall, Gland Pharma has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Other Long-Term Liabilities compare to ZTS?
Gland Pharma's Other Long-Term Liabilities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Gland Pharma and its competitors. Gland Pharma's current Other Long-Term Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,241.20, compared to a current price of ₹2,858.60 — trading 27.5% above its estimated fair value. The current Other Long-Term Liabilities is ₹0 Mil. Gland Pharma's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Other Long-Term Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,858.60 is trading 27.5% above its estimated GF Value™ of ₹2,241.20. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Other Long-Term Liabilities: ₹0 Mil
  • GF Value™: ₹2,241.20 vs. price of ₹2,858.60 (27.5% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
80GF Score

Get the complete analysis for NSE:GLAND

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,858.60
Price
₹2,241.20
GF Value